Redistribution of TNF Receptor 1 and 2 Expression on Immune Cells in Patients with Bronchial Asthma
Alina Alshevskaya,
Julia Zhukova,
Fedor Kireev,
Julia Lopatnikova,
Irina Evsegneeva,
Daria Demina,
Vera Nepomniashchikch,
Victor Gladkikh,
Alexander Karaulov,
Sergey Sennikov
Affiliations
Alina Alshevskaya
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk 630099, Russia
Julia Zhukova
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk 630099, Russia
Fedor Kireev
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk 630099, Russia
Julia Lopatnikova
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk 630099, Russia
Irina Evsegneeva
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow 101000, Russia
Daria Demina
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk 630099, Russia
Vera Nepomniashchikch
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk 630099, Russia
Victor Gladkikh
Biostatistics and Clinical Trials Center, Novosibirsk 630099, Russia
Alexander Karaulov
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow 101000, Russia
Sergey Sennikov
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk 630099, Russia
Background: The co-expression patterns of type 1 and 2 tumor necrosis factor (TNF)-α membrane receptors (TNFR1/TNFR2) are associated with the presence, stage, and activity of allergic diseases. The aim of this study was to assess the expression levels and dynamics of TNFRs on immune cells and to assess associations between their expression and severity of bronchial asthma (BA). Methods: Patients with severe (n = 8), moderate (n = 10), and mild (n = 4) BA were enrolled. As a comparison group, data from 46 healthy volunteers (HV) were accessed. Co-expression of TNFR1/2 was evaluated as a percentage of cells and the number of receptors of each type per cell. Multivariate logistic regression analysis was used to identify diagnostic biomarkers of BA. Results: More than 90% of the monocytes in patients with mild BA were TNFR1+TNFR2+ but had significantly lower TNFR1 expression density compared with HV (7.82- to 14.08-fold, depending on disease severity). Lower percentages of the TNFR+ B-lymphocytes were observed in combination with significantly lower receptors density in BA compared with HV (2.59- to 11.64-fold for TNFR1 and 1.72- to 3.4-fold for TNFR2, depending on disease severity). The final multivariate model for predicting the presence of BA included the percentage of double-positive CD5+ B-lymphocytes and average number of TNFR1 molecules expressed on cytotoxic naive T-lymphocytes and T-helper cells (R2 = 0.87). Conclusions: The co-expression patterns of TNFRs on immune cells in BA differed significantly compared with HV. The expression differences were associated with disease severity. TNFR1 expression changes were key parameters that discriminated patients with BA from those with HV.